Means and methods for treating DLBCL

摘要

The present invention provides means and methods for treating diffuse large B cell lymphoma (DLBCL). Specifically, a bispecific CD19×CD3 antibody which engages T cells via its CD3 binding portion and concomitantly binds to CD19 on the surface of in particular, lymphoma cells via its CD19 binding portion (i.e. a bispecific T cell engager, “BiTE”) is administered for use in the treatment of tumorous mass of lymophoreticular tissue and/or extranodal lymphoma caused by DLBCL in a patient.

主权项

1. A method for treating a tumorous mass of lymph node tissue and/or extranodal lymphoma in a patient suffering from relapsed and/or refractory diffuse large B cell lymphoma (DLBCL), the method comprising the step of administering to the patient (i) a composition comprising an effective amount of a CD19×CD3 bispecific antibody in a step-wise application, whereby a first dose between 1 and 15 μg/m2/d of the CD19×CD3 bispecific antibody is administered daily for a first period of time from 3 to 10 days, a second dose between 1 and 15 μg/m2/d of the CD19×CD3 bispecific antibody is administered daily for a second period of time from 3 to 10 days, and a third dose between 15 and 60 μg/m2/d of the CD19×CD3 bispecific antibody is administered daily for a third period of time from 8 to 78 days; and (ii) a composition comprising an effective amount of a glucocorticoid to ameliorate adverse neurological effects of the antibody in the patient, whereby the glucocorticoid is administered prior to and after the CD19×CD3 bispecific antibody is administered.